IPLA
Pharmaceutical compound
iPLA, also known as N-isopropyllysergamide, as well as lysergic acid isopropylamide (LAiP), is a serotonin receptor modulator and possible serotonergic psychedelic of the lysergamide family related to lysergic acid diethylamide (LSD). It is the analogue of LSD in which the N,N-diethyl groups have been replaced with an N-isopropyl group.
In an early study, iPLA showed about 22.2% of the antiserotonergic activity of LSD in the isolated rat uterus. The drug is known to bind with high affinity (Ki) to the serotonin 5-HT2A, 5-HT2C, and 5-HT1A receptors. It is a potent agonist of the serotonin 5-HT2A receptor. iPLA fully substituted for LSD in rodent drug discrimination tests with a potency of about half that of LSD itself, findings which suggest that iPLA may have psychedelic effects in humans.
iPLA was first described in the scientific literature by Albert Hofmann and colleagues by 1955. Subsequently, it was studied in more detail by David E. Nichols and colleagues in the 1990s. It is not a controlled substance in Canada as of 2025.
Sources and credits
This article is adapted from the Wikipedia article “IPLA”, written by its contributors and licensed under CC BY-SA 4.0. Fathomly has changed the layout, removed citation markers, navigation and maintenance notices, and adjusted punctuation. This adapted version is shared under the same license. For references, see the original article.
Images, from Wikimedia Commons:
- IPLA structure.svg by AlyInWikiWonderland, Public domain
Fathomly is not affiliated with or endorsed by the Wikimedia Foundation. Spotted a problem? Tell us.
